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Background: Acute promyelocytic leukemia (APL) is a model for synergistic target cancer therapy using all-trans
retinoic acid (ATRA) and arsenic trioxide (ATO), which yields a very high 5-year overall survival (OS) rate of 85 to
90%. Nevertheless, about 15% of APL patients still get early death or relapse. We performed this study to address
the possible impact of additional gene mutations on the outcome of APL.
Methods: We included a consecutive series of 266 cases as training group, and then validated the results in a
testing group of 269 patients to investigate the potential prognostic gene mutations, including FLT3-ITD or
-TKD, N-RAS, C-KIT, NPM1, CEPBA,WT1, ASXL1, DNMT3A,MLL (fusions and PTD), IDH1, IDH2 and TET2.
Results:More high-risk patients (50.4%) carried additional mutations, as compared with intermediate- and low-
risk ones. The mutations of epigenetic modiﬁer genes were associated with poor prognosis in terms of disease-
free survival in both training (HR = 6.761, 95% CI 2.179–20.984; P = 0.001) and validation (HR = 4.026, 95%
CI 1.089–14.878; P = 0.037) groups. Sanz risk stratiﬁcation was associated with CR induction and OS.
Conclusion: In an era of ATRA/ATO treatment, bothmolecular markers and clinical parameter based stratiﬁcation
systems should be used as prognostic factors for APL.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acute promyelocytic leukemia (APL) is a distinct subtype of acute
myeloid leukemia with typical chromosomal translocation t(15; 17),
which results in the formation of leukemogenic chimerical gene PML–
RARα. The PML–RARα oncoproteins exert a dominant-negative effect
on their normal counterparts, PML and RARα, which are involved in
the regulation of the physiological processes of myeloid differentiation,
apoptosis and DNA replication/repair (Chen et al., 1994; Degos et al.,
1995; Fenaux et al., 1994; Huang et al., 1988; Niu et al., 1999; Villa
et al., 2007; Wang et al., 2010; Zhu et al., 2007). Bleeding tendencyMedical Genomics, Shanghai
Shanghai Jiao Tong University
enter of Systems Biomedicine,
), zchen@stn.sh.cn (Z. Chen),
. This is an open access article undercaused by either hypoﬁbrinogenemia or disseminated intravascular co-
agulation (DIC) and accumulation of promyelocytes in the bonemarrow
(BM) are common clinical features (Chen et al., 1994; Degos et al., 1995;
de la Serna et al., 2008; Tallman and Altman, 2009).
The revolutionary introduction of all-trans retinoic acid (ATRA) has
signiﬁcantly changed the treatment paradigm of APL (Huang et al.,
1988; Muindi et al., 1992; Sanz and Lo-Coco, 2011). The terminal differ-
entiation of APL cells upon effect of ATRA, instead of cytolysis by con-
ventional chemotherapy, ameliorates the coagulopathy of the disease
and increases the complete remission (CR) rate of induction (Tallman
and Altman, 2009; Muindi et al., 1992; Sanz and Lo-Coco, 2011; Zhu
et al., 1999). Currently, ATRA based treatment has become the standard
care of the APL which signiﬁcantly prolongs disease-free survival (DFS)
and overall survival (OS) (Fenaux et al., 1994; Avvisati et al., 1996; De
Botton et al., 1998; Estey et al., 1999, 2005; Hu et al., 2009; Shen et al.,
2004). Since the 1990s, arsenic trioxide (ATO) has yielded break-
throughs in treating both relapsed and newly diagnosed APL patients
and has been shown to induce differentiation and apoptosis of APL
cells. Mechanistic exploration proved that ATRA and ATO exert directthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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oncoprotein. While ATRA targets the ligand-binding domain (LBD) of
RARαmoiety, arsenic binds to adjacent cysteine residues locatedwithin
the RING, B Boxes and coiled coil (RBCC) domain of PML. Both agents in-
duce degradation of the fusion protein. Interestingly, arsenic binding re-
sults in an oligomerization of PML–RARα and increases its interaction
with the small ubiquitin-like protein modiﬁer (SUMO)-conjugating en-
zyme UBC9, leading to enhance SUMOylation. The sumoylated fusion
protein on its turn recruits the ubiquitin E3 ligase RNF4 and undergoes
proteasome-mediated degradation (Chen et al., 1996; Jeanne et al.,
2010; Rajendra et al., 2012; Zhang et al., 2010; Zhu et al., 1997). In addi-
tion, leukemia-initiating cells (LICs), which are responsible for relapse
of leukemia, could be cleared by ATRA/ATO based treatment in murine
models, providing further rationale of combined use of the two agents
(Au et al., 2001; Ito et al., 2008; Nasr et al., 2008, 2010; Zhou et al.,
2010). The potential synergic effect of ATRA and ATO owing to different
modes of action represents thus a strong impetus for the trial of combi-
nation of ATRA and ATO in the newly diagnosed APL. Indeed, ATRA/ATO
combination as ﬁrst line induction therapy with chemotherapy as con-
solidation has not only brought a shortened time to achieve CR but
more importantly reduced disease burden and substantially enhanced
survival as compared to patients treated with each of the two agents
in an initial randomized trial at the Shanghai Institute of Hematology
(SIH) (Hu et al., 2009; Shen et al., 2004). Then in the extended arm of
ATRA/ATO/chemotherapy combination for 85 APL patients, remarkable
5-year event-free survival (EFS) and OS rates of 89.2% ± 3.4% and
91.7% ± 3.0%, respectively, were achieved (Hu et al., 2009). The results
were then conﬁrmed by several hematology/oncology centers in West-
ern countries. Lo-Coco et al., 2013 recently reported that by using ATRA
and ATO alone in the treatment of newly diagnosed low-to-
intermediate-risk patients, the CR rate could be as high as 100% with a
2 year EFS of 97% (Lo-Coco et al., 2013).
Laboratory and clinical evidence strongly suggests that mutations of
LBD of RARα and B box2 of PML in PML–RARα are responsible for resis-
tance to ATRA and ATO, respectively (Jeanne et al., 2010; Zhang et al.,
2010; Goto et al., 2011). However, these mutations generally occur at
the time of relapse. Previously we and others observed that at disease
presentation, some other molecular events could co-exist with PML–
RARα such as mutations of NRAS, KRAS, FMS-like tyrosine kinase 3
[with internal tandem duplication (FLT3-ITD) or FLT3 point mutations
(FLT3-TKD)] and JAK1. In APL patients treated with ATRA and chemo-
therapy, thesemutationsmight exert potential impact on the biological
behavior, clinical manifestation and treatment outcome (Chan et al.,
2006; Rampal and Levine, 2011; Shen et al., 2011). More recently,
when new genetic markers such as DNMT3A and IDH1/2 were used for
mutation screening in APL and genomic data of some APL cases were
available (Shen et al., 2011; Wang et al., 2013), it was revealed that
still other genemutations could exist and be related to disease outcome.
In this study, we have investigated the genemutational status of APL
in addition to PML–RARα to clarify their potential biological and clinical
impact among patients treated with ATRA/ATO based protocol in an
attempt to further improve the stratiﬁcation system of APL.
2. Methods
2.1. Patients and Treatment
A total of 535 newly diagnosed APL patients were enrolled from
February 2001 to February 2014, whose samples were sent to SIH for
molecular assessment. The training group consisted of 266 patients
whowere treated by Shanghai APL regimen with ATRA/ATO based pro-
tocol in SIH afﬁliated centers (Hu et al., 2009), during February 2001 and
March 2008. The validation group consisted of 269 patients in three
multi-center clinical trials from SIH, Zhejiang Institute of Hematology
(ZIH) and Peking University Institute of Hematology (Zhu et al., 2013).
All cases in these three groups were treated with the same ATRA/ATObased protocol as in the training group. The detailed treatment proto-
cols are seen in Supplementary Fig. 1.
The diagnosis of the disease was established according to the
nomenclature of WHO for leukemia. Cytogenetic and molecular
examinations of t(15;17) and/or PML–RARα were performed as previ-
ously described. Based on the levels of initial WBC and platelets by
Sanz risk stratiﬁcation, the patients could be classiﬁed into 3 groups:
high-risk, WBC above 10 × 109/L; low-risk, WBC below 10 × 109/L and
platelet more than 40 × 109/L, and intermediate-risk, all the
remaining cases, respectively (Sanz et al., 2000).
This study was approved by the Institutional Review Board (IRB) of
all participating hospitals. All patients were given informed consent
for both treatment and cryopreservation of bone marrow (BM) and
peripheral blood (PB) according to the Declaration of Helsinki.
2.2. Molecular Genetic Analysis
Genomic DNA and total RNA were extracted as previously reported.
Regular RT-PCR of 3 distinct [long (L), short (S), and variant (V)] types of
PML–RARα transcripts were analyzed as described previously (Dicker
et al., 2011).
Gene mutational status analysis was performed in all patients. A se-
ries of gene markers were chosen based on our previous study on a
group of 388 APL patients (Shen et al., 2011) and on detailed analysis
of the genomic data in the literature (Cancer Genome Atlas Research
N, 2013). Mutations including FLT3-ITD or -TKD, N-RAS, C-KIT, NPM1,
CEPBA, WT1, ASXL1, DNMT3A, MLL, IDH1, IDH2 and TET2 genes were
assessed by distinct approaches. A chip-based matrix assisted laser de-
sorption/ionization time-of-ﬂight mass spectrometry (MALDI–TOF
MS) analysis system (iPLEXTM, Sequenom, San Diego, CA, USA) was
used to analyze the mutational status of FLT3-TKD, N-RAS, NPM1, and
whole gene sequencing was applied to investigate the mutations of
FLT3-ITD, C-KIT, CEPBA, WT1, ASXL1, DNMT3A, IDH1, IDH2 and TET2
genes (Shen et al., 2011; Bashey et al., 1992; Bowen et al., 2005;
Damm et al., 2011). Six MLL-related common fusion genes including
MLL-AF9,MLL-AF10,MLL-AF6,MLL-ELL,MLL-ENL andMLL-AF17were de-
tected via a multiplex RT-PCR strategy (Dicker et al., 2011). The muta-
tional status ofMLL-PTD was determined by RT-PCR technique.
A RT-PCR was performed to detect mutations of PML–RARα in re-
lapsed patients. 1 μg of total RNA was reversely transcribed to cDNA
using M-MLV reverse transcriptase kit (Invitrogen). Then r-Taq
polymerase kit (Takara) was used to perform PCR and ampliﬁed PCR
fragments were subjected to Sanger sequencing. Since recent studies
had revealed the enrichment of PMLmutations in the RBCC B2 domain
and of RARαmutations in LBD domain (Goto et al., 2011), the primers
for PCR ampliﬁcation of these two domains were designed as follows:
PML-RBCC-Forward 5′-CAGATTGTGGATGCGCAGGC and PML-RBCC-
Reverse 5′-CAGCCGACTGGCCATCTCCT;RARA-LBD-Forward5′-GAAGAA
GAAGGAGGTGCCCAandRARA-LBD-Reverse 5′-CATCTTCAGCGTGATCAC
CC. The PCR was carried out in the reaction mixtures according to the
provided protocol of rTaq and ampliﬁcation was under the following
conditions: 95 °C for 5 min of one cycle, followed by 35 cycles of 30 s
at 95 °C, 40 s at 58 °C and 50 s at 72 °C, and a ﬁnal stage of 5 min at
72 °C. The resulting data of Sanger sequencing were analyzed by
software Chromas lite (Technelysium).
2.3. Statistical Analyses
Fisher's exact P test was used to compare the difference of CR rates
which was deﬁned according to the criteria of International Working
Group (Cheson et al., 2003). One way Anova test was used to compare
the age, WBC count and BM blasts at diagnosis in different groups. OS
was measured from the date of disease diagnosis to death (failure) or
alive at the last follow-up (censored). DFS was deﬁned as the duration
from the documentation of CR to treatment failure such as relapse, re-
fractory disease, death, or alive in CR at the last follow-up (censored)
Table 1
Clinical characteristics of the patients.
Training group (n = 266) Validation group (n = 269)
Age (years)
Mean 36.8 ± 16.0 39.6 ± 13.2
Range 14–77 14–76
Gender
Male 136 (51.2) 140 (52.0)
Female 130 (48.8) 129 (48.0)
WBC count, ×109/L
Median 2.8 2.5
Range 0.3–205.7 0.3–122.2
Risk stratiﬁcation
High 57 (21.4) 74 (27.5)
Intermediate 131 (49.2) 117 (43.5)
Low 78 (29.3) 78 (20.0)
FLT3
Mutated 34 (12.8) 50 (18.9)
ITD 22 (64.7) 35 (70.0)
TKD 12 (35.3) 15 (30.0)
Not mutated 232 (87.2) 215 (81.1)
Failed 0 4
RAS
Mutated 14 (5.4) 9 (3.9)
Not mutated 244 (94.6) 242 (96.1)
Failed 8 18
WT1
Mutated 11 (4.4) 13 (4.9)
Not mutated 238 (95.6) 253 (95.1)
Failed 17 3
EMG (%)
Mutated 14 (5.3) 21 (7.8)
Not mutated 224 (94.7) 219 (92.2)
Failed 28 29
WBC, white blood cell; BM, bone marrow; and n, number of patients.
“Failed” refers to the samples without detection results due to quality problems.
EMG refers to a group of epigenetic modiﬁer genes investigated in this work.
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hazard ratio analyses were used to calculate and compare the OS and
DFS, respectively. Cox model was used for the multivariate analysis of
associations of survival and potential prognostic factors. A limited
backward selection procedure was used to exclude redundant variates
(Gill, 1992). The above statistical procedures were all performed with
the SPSS statistical software package, version 16.0.Table 2
Gene mutations and clinical aspects.
Gene mutations Gender
No. of the patients
Mean
Male Female
FLT3-ITD or -TKD (Failed = 4) Mutated 54 30 37.2 ±
Not mutated 220 227 38.3 ±
P = 0.012 P = 0
N-RAS (Failed = 26) Mutated 14 9 35.1 ±
Not mutated 252 234 38.2 ±
P = 0.523 P = 0
WT-1 (Failed = 20) Mutated 15 9 35.9 ±
Not mutated 251 240 38.3 ±
P = 0.403 P = 0
EMG (Failed = 57)a Mutated 23 12 40.1 ±
Not mutated 222 221 37.9 ±
P = 0.081 P = 0
WBC, white blood cell; BM, bone marrow; and no., number.
“Failed” refers to the samples without detection results due to quality problems.
EMG refers to a group of epigenetic modiﬁer genes investigated in this work.
One patient with IDH1mutation but failed in TET2 analysis was considered as EMGmutated.
a Failed number:MLL fusion gene/PKD mutations (n = 1), DNMT3A (n = 13), IDH1 (n = 263. Results
3.1. Characteristics of Patients
The demographic data of 535 APL patients in both training (266
cases) and validation (269 cases) groups were depicted in Table 1. The
clinical variables including age, gender, and median WBC count were
similar between the two cohorts. The validation group seemed to con-
tain more FLT3mutation cases and high-risk patients. However, the fre-
quency of ITD and TKD in training and validation groups (P = 0.641)
was similar.3.2. Molecular Aspects of the Patients
In the pooled data of 535 patients, FLT3-ITD or -TKD (84/531, 15.8%),
N-RAS (23/509, 4.5%) andWT-1 (24/515, 4.7%) mutations were identi-
ﬁed as the threemost common additional genemutations. Notably, mu-
tations of epigenetic modiﬁer genes (EMGs), such as DNMT3A (0.3%),
TET2 (4.5%), IDH1 (0.4%), IDH2 (0.2%) and ASXL1 (1.6%), could co-exist
with PML–RARα fusion, whereas no PTD mutation or fusion of MLL
was noted in any cases, suggesting a mutual exclusivity betweenMLL
abnormalities and the PML–RARα characteristic of APL. Put together,
35 (6.5%) out of 535 patients harbored EMG mutations.
As shown in Table 2, the FLT3-ITD/TKD mutations and N-RASmuta-
tions were associated with a phenotype of high WBC count (P b 0.001
and P = 0.001, respectively), whereas FLT3 mutations also showed a
male tendency (P = 0.012). When the possible relationships between
distinct gene mutations were analyzed, 164 patients (30.7%) carried at
least one of the above mentioned mutations, while 18 patients (3.4%)
carried double or triple additional mutations. EMG mutations tended
to co-exist with other mutations. Among 18 patients with two or
three gene mutations, 11 (61.1%) cases contained EMG abnormalities
(P b 0.001).
The correlations between additional mutations and clinical risk
groups were addressed (Fig. 1). Of note, over half of patients in high-
risk group carried these mutations (66/131, 50.4%), signiﬁcantly higher
than those in the intermediate- (62/248, 25.0%) and low-risk group
(36/156, 23.1%) (P b 0.001, respectively). High-risk patients tended to
carry more signaling molecule gene mutations, such as FLT3 (P b 0.001),
as compared with low-intermediate risk ones. The distributions of other
mutations were similar among different groups as shown in Table 2.age (yrs) Median WBC count, ×109/L
(range)
Sanz risk stratiﬁcation
High Low and Intermediate
15.3 8.85 (0.5–205.7) 39 45
14.5 2.3 (0.3–122.2) 91 356
.577 P b 0.001 P b 0.001
12.4 8.0 (0.54–78.9) 9 14
14.8 2.5 (0.3–205.7) 115 371
.317 P = 0.001 P = 0.132
16.0 2.7 (0.6–72.0) 9 15
14.6 2.7 (0.3–205.7) 122 369
.440 P = 0.832 P = 0.148
15.5 2.4 (0.8–58.4) 11 24
14.5 2.8 (0.3–205.7) 112 331
.395 P = 0.866 P = 0.425
), IDH2 (n = 24), ASXL1(n = 31), and TET2 (n = 27).
Fig. 1.Correlation between genemutations and clinical risk groups. High-risk patients containedmoremutations additional to PML–RARα (50.4%, 66/131) as comparedwith intermediate-
(25.0%, 62/248, P b 0.001) and low-risk (23.1%, 36/156, P b 0.001) groups.
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In the training group, 251 out of 266 (94.4%) APL cases treated with
ATRA/ATO combination therapy in SIH-related centers during 2001 to
2008 achieved CR. Among 269 cases treated with the same regimen
but in a multi-center trial setting as validation group (Table 3), 253
out of 269 patients (94.1%) reached to CR. In univariate analysis for po-
tential prognostic factor on induction outcome, Sanz low-risk patients
could achieve a higher CR rate than the intermediate-high-risk patients
in both training and validation groups (P = 0.007 for both training and
validation groups, Table 3). No adverse effects of FLT3-ITD/TKD, N-RAS,
WT1 and EMG mutations were observed on CR induction.
A multivariate analysis was performed in 467 pooled patients of
training and validation groups, who were with complete molecular re-
sults of FLT3,N-RAS,WT1, and all EMGmutations. Sanz risk stratiﬁcation
(P = 0.001, OR 2.815 [1.566–5.059]) and WT1 (P = 0.048, OR 0.297
[0.089–0.988]) were correlated with the results of CR induction. The
complete set of covariates that entered into multivariate model was
shown in Table 5.Table 3
The relationship between Sanz risk stratiﬁcation or gene mutational status and CR rate.
Training group Validation group
CR no. (%) P value CR No. (%) P value
Sanz risk stratiﬁcation
High 52/57 (91.2) 0.007a 65/74 (87.8) 0.007a
Intermediate 121/131 (92.3) 110/117 (94.0)
Low 78/78 (100) 78/78 (100)
FLT3-ITD or -TKD
Mutated 32/34 (94.1) 0.697 47/50 (94.0) 1.000
Not mutated 219/232 (94.4) 202/215 (94.0)
N-RAS
Mutated 13/14 (92.9) 0.552 9/9 (100) 1.000
Not mutated 231/244 (94.7) 227/242 (93.8)
WT1
Mutated 9/11 (81.8) 0.136 11/13 (84.6) 0.179
Not mutated 225/238 (94.5) 239/253 (94.5)
EMG
Mutated 13/14 (92.9) 0.217 19/21 (90.5) 0.068
Not mutated 221/224 (98.7) 205/209 (98.1)
Double or triple mutations
Yes 8/9 (88.9) 0.412 8/9 (88.9) 0.429
No 243/257 (94.6) 245/260 (94.2)
a Low risk vs. intermediate-risk or high-risk.Early death (ED) constituted the main reason of induction failure.
Among the total 31 ED cases, themain causes of death were intracranial
hemorrhage (22 patients), followed by differentiation syndrome (6
patients) and cerebral/cardiac infarction (3 patients).
3.4. Survival Analysis
In univariate analysis, Sanz risk stratiﬁcationwas strongly associated
with the prognosis in terms of OS (HR = 0.402, 95% CI 0.223–0.725;
P = 0.002) in training group, which was conﬁrmed by validation
group OS (HR= 0.323, 95% CI 0.165–0.632; P = 0.001) (Fig. 2A–D). In-
terestingly, EMGmutations suggested an inferior treatment outcome in
terms of OS (HR = 3.335, 95% CI 1.139–9.759; P = 0.028) and DFS
(HR = 6.761, 95% CI 2.179–20.984; P = 0.001) in training group, with
a median follow-up of 84 months (Fig. 3A and B). We then addressed
the survival impact of clinical and molecular factors in 269 cases of val-
idation group, with a median follow-up of 38 months. Although EMG
mutations did not have a statistically signiﬁcant effect on OS (P =
0.119, Fig. 3C), they profoundly affected the DFS (HR = 4.026, 95% CI
1.089–14.878; P = 0.037, Fig. 3D). No prognostic effects of FLT3-ITD/
TKD on OS and DFS were observed in either training or validation
groups (Fig. 4A–D). Similarly, no signiﬁcant effects of WT1 and NRAS
mutations were noted on treatment outcomes in the two groups (Sup-
plementary Table 1). Although double or triple mutations suggested
poor prognosis in training group, they were not proved in validation
group (Supplementary Fig. 2).
In the pooled set of 535 patients, the median follow-up time was
48 months. The estimated 5-year survival rates for different clinical
and gene mutational status were shown in Table 4. In the multivariate
analysis of 467 patients, the independent factors indicating poor prog-
nosis included Sanz risk stratiﬁcation for OS (OR = 0.386, 95% CI
0.247–0.605, P b 0.001) and EMG mutations for OS (OR = 2.721, 95%
CI 1.212–6.105, P = 0.015) and DFS (OR = 4.702, 95% CI 1.895–
11.671, P = 0.001), respectively (Table 5).
3.5. Point Mutations in Coding Sequences of PML–RARα in Relapsed
Patients With EMG Mutations
To investigate the possible association of point mutations in PML–
RARα to ATRA/ATO sensitivity, we examined the coding sequences of
PML–RARα in ﬁve pairs of samples at initial diagnosis and the ﬁrst re-
lapse in patients with EMG mutations. PMLmutation was identiﬁed in
AB
C
D
Number at risk
High 57 36 20 2
Intermediate 131 80 37 6
Low 78 49 25 3
HR=0.402, 95% CI 0.223-0.725; p=0.002
HR=0.578, 95% CI 0.288-1.160; p=0.123
Number at risk
High 52 34 18 1
Intermediate 121 76 35 4
Low 78 46 22 1
HR=0.534, 95% CI 0.257-1.110; p=0.093
HR=0.323, 95% CI 0.165-0.632; p=0.001
Number at risk
High 74 56 33 10 2
Intermediate 117 97 52 15 3
Low 78 69 38 9 4
Low-risk (n=78)
Intermediate-risk (n=131)
High-risk (n=57)
Low-risk (n=78)
High-risk (n=52)
Intermediate-risk (n=121)
Low-risk (n=78)
Intermediate-risk (n=117)
High-risk (n=74)
Low-risk (n=78)
Intermediate-risk (n=110)
High-risk (n=65)
Number at risk
High 65 51 29 9 1
Intermediate 110 95 45 12 3
Low 78 66 34 8 2
Fig. 2.Kaplan–Meier curves for overall survival (OS) and disease-free survival (DFS) according to Sanz's risk stratiﬁcation in univariate analysis. (A, B)OS andDFS of different risk groups in
training group. (C, D) OS and DFS of different risk groups in validation group.
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plementary Fig. 3), which was associated with drug resistance and
cause of death. No mutations were identiﬁed in the RARα portion of
the fusion transcripts in all ﬁve pairs of samples. In the four patients
without any mutations of PML–RARα, three were still sensitive to
ATRA/ATOwhile the other casewith a DNMT3Amutation at initial diag-
nosis developed a CNS leukemia and died soon.
4. Discussion
ATRA plus chemotherapy (anthracyclines alone or with Ara-C) has
been used as routine practice for treatment of APL in hematology/oncol-
ogy centers worldwide (Degos et al., 1995; Avvisati et al., 1996; De
Botton et al., 1998; Estey et al., 2005; Lo-Coco et al., 2013; Sanz et al.,
2000). ATO was tested in re-induction in relapsed patients with a CR
rate more than 80% (Tallman and Altman, 2009; Shen et al., 2004,
2001). We initially proposed simultaneous use of ATRA and ATO in
newly diagnosed patients based on several lines of evidence. First,ATO and ATRA target, respectively, the N- and C-terminals of PML–
RARα and modulate key pathways involved in apoptosis/differentia-
tion. Hence a combined use of the two agents may bring synergistic ef-
fect (Wang et al., 2010; Zhang et al., 2010). Second, evidence from pre-
clinical study showed that ATRA/ATO combination could signiﬁcantly
reduce the tumor burden or even eliminate the disease in experimental
APL animal models (Lallemand-Breitenbach et al., 1999). Third, tran-
scriptome/proteome analysis of APL cells upon the joint effect of the
two agents showed enhanced induction of differentiation/apoptosis as-
sociated pathways in the absence of obvious induction of pathways re-
lated to cell toxicity (Zheng et al., 2005). Fourth, the ATO-induced
second or third CR in patients relapsed after treatment with ATRA/che-
motherapy usually didn't last long.
Indeed, with the ATRA/ATO combination therapy, the clinical out-
come of APL has dramatically changed and the disease has been trans-
formed from highly fatal to highly curable in a great majority of
patients (Chen et al., 1994; Fenaux et al., 1994; Huang et al., 1988; Niu
et al., 1999; Tallman and Altman, 2009; Hu et al., 2009; Shen et al.,
A C
B D
EMG III m+vsm-: HR=3.335, 95% CI 1.139-9.759; p=0.028 EMG III m+vsm-: HR=2.366, 95% CI 0.801-6.992; p=0.119
Number at risk
EMG m+ 14 7 4
EMG m- 224 138 71 10
EMG m+vsm-: HR=6.761, 95% CI 2.179-20.984; p=0.001
Number at risk
EMG m+ 13 6 3
EMG m- 211 131 65 5
Number at risk
EMG m+ 21 17 11 3 1
EMG m- 219 179 100 27 8
EMG m+vsm-: HR=4.026, 95% CI 1.089-14.878; p=0.037
EMG m- (n=224)
EMG m+ (n=14)
EMG m- (n=219)
EMG m- (n=211)
EMG m+ (n=13)
EMG m+ (n=19)
EMG m- (n=205)
EMG m+ (n=21)
Number at risk
EMG m+ 19 14 9 2
EMG m- 205 172 88 23 5
Fig. 3. Kaplan–Meier curves for overall survival (OS) and disease free survival (DFS) according to EMG mutational status in univariate analysis. (A, B) OS and DFS of patients with EMG
mutations in training group. (C, D) OS and DFS of patients with EMG mutations in validation group.
568 Y. Shen et al. / EBioMedicine 2 (2015) 563–5712004; Zhang et al., 2010; Zhu et al., 2013, 1997; Ito et al., 2008; Zhou
et al., 2010; Lo-Coco et al., 2013; Shen et al., 2001). Recent evidence
from Huang et al. also proved that ATRA in combination of an oral arse-
nic compound, As4S4, is as effective as ATRA/ATO (Zhu et al., 2013). A
comparison of the results between a historic control group of 97 cases
treated with ATO as rescue for relapse after ATRA/chemotherapy regi-
men (ATRA→ ATO group) yielded an outcome signiﬁcantly inferior to
that achieved by simultaneous use of the two medicines in 535 cases
in this series (ATRA/ATO group). With a median follow-up time of
60 months, the 5 year OS and DFS rates were respectively 68.3 ± 4.8%
and 76.4 ± 5.4% in ATRA → ATO group as compared to 89.9% ± 1.4%
and 92.9 ± 1.3% in ATRA/ATO group (P b 0.001 for both OS and DFS,
Supplementary Fig. 4A, B). However, APL is not a homogenous disease
and can be stratiﬁed into low-, intermediate- and high-risk groups ac-
cording to clinical parameters, such as WBC and platelet (Sanz and
Lo-Coco, 2011; Sanz et al., 2000). Even with ATRA/ATO treatment, a siz-
able portion of high-risk patients (17.6% in this study) still experienced
difﬁcult induction intercourse, disease recurrence and short survival. A
low percentage of cases in low- and intermediate-risk groups still got re-
lapse (3.2% and 5.2%, respectively). Therefore, it is important to identifymore sensitive markers to have a better stratiﬁcation system for APL
(Sanz and Lo-Coco, 2011).
Adverse effects of gene mutations additional to PML–RARα fusion,
especially FLT3-ITD/TKD, on the prognosis of APL drew attentions in re-
cent years; however, the results were controversial among different re-
search groups (Beitinjaneh et al., 2010). Previous prognostic studies had
often been limited by the diversity of the treatment protocols, and the
absence of ATO in the front-line treatment (Avvisati et al., 1996; Shen
et al., 2004; Zhou et al., 2010; Lo-Coco et al., 2013; Zhu et al., 2013;
Lou et al, 2013.; Raffoux et al., 2003). In thiswork,we examined the pos-
sible effects of additional genemutations in two large cohorts of APL pa-
tients with homogenous ATRA/ATO treatment. It was found that a
number of gene point mutations or insertion events could occur in
APL in the presence of fusion gene, with themutations of signalingmol-
ecules being themost frequent ones. Mutations of FLT3 and N-RASwere
signiﬁcantly correlated with high initial WBC count at diagnosis. With
regard to risk groups, we discovered that nearly half of the high-risk pa-
tients (50.4%) carried additional mutations, mostly those of FLT3 and N-
RAS, which could reﬂect themolecular complexity in this group as com-
pared with intermediate- and low-risk ones. A large body of evidence
A C 
B D
FLT3 m+vsFLT3 m-: HR=1.292, 95% CI 0.443-3.763; p=0.639
Number at risk
FLT3 m+ 34 23 13 3
FLT3 m- 232 142 69 8
FLT3 m- (n=232)
FLT3 m+ (n=34)
FLT3 m+vsFLT3 m-: HR=2.348, 95% CI 0.757-7.280; p=0.139
Number at risk
FLT3 m+ 32 21 11 1
FLT3 m- 219 135 64 5
FLT3 m+vsFLT3 m-: HR=0.973, 95% CI 0.329-2.875; p=0.960
FLT3 m+vsFLT3 m-: HR=1.226, 95% CI 0.342-4.398; p=0.754
FLT3 m- (n=219)
FLT3 m+ (n=32)
FLT3 m+ (n=50)
FLT3 m- (n=215)
FLT3 m+ (n=47)
FLT3 m- (n=201)
Number at risk
FLT3 m+ 50 41 19 2
FLT3 m- 215 178 103 31 9
Number at risk
FLT3 m+ 47 39 17 2
FLT3 m- 201 170 90 26 7
Fig. 4. Kaplan–Meier curves for overall survival (OS) and disease free survival (DFS) according to FLT3mutational status in univariate analysis. (A, B) OS and DFS of patients with FLT3
mutations in training group. (C, D) OS and DFS of patients with FLT3mutations in validation group.
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tures at disease onset, but also potentially associated with drug re-
sponse and prognosis of AML. Nevertheless, the impact of certain
biomarkers can be deeply affected by treatment factors. To this end, it
may be noteworthy that although FLT3-ITD or -TKD mutations exerted
negative impact on the OS and DFS in historic control of 97 patients in
ATRA → ATO group (Supplementary Fig. 5A, B), the introduction of
ATO into theﬁrst line treatment in ATRA/ATO group abrogated this neg-
ative impact in both training and validation groups (Fig. 4A–D). In con-
trast, the adverse effects of EMG abnormalities were not inﬂuenced by
ATRA/ATO combination, especially for DFS. The mechanism underlying
negative prognostic effect of EMG mutations remains unclear. It is as-
sumed that several factors may contribute to its effect. First, by altering
DNAmethylation and/or histonemodiﬁcation patterns, EMGmutations
on their own can profoundly affect the gene expression proﬁles in favor
of the acquisition of growth and survival advantages of hematopoietic
stem/progenitor cells (Shen et al., 2011; Jasielec et al., 2014; Jeong
et al., 2014; Yan et al., 2011) and some of them have been shown to
be leukemogenic in animal models (Chen et al., 2009, 2013). Hence,the presence of these mutations could render APL stem/progenitor
cells even more resistant to current therapies. Second, EMG mutations
tended to co-exist with other mutations (in this series of APL, 11/35,
P b 0.001), which may add complexities to leukemogenesis. Although
the negative effect of multiple mutations could not be proved in valida-
tion group, longer follow-up iswarranted. Third, genemutations associ-
ated with epigenetic regulations are involved in DNA repair (Schar and
Fritsch, 2011), whose abnormalities could make APL stem/progenitor
cells prone to mutational events especially under the selective pressure
of ATRA/ATO, such as those of PML–RARα gene, which potentially leads
to the relapse of the disease. Of course, more clinical and experimental
evidence should be accumulated to support the above view points.
Sanz risk stratiﬁcation is still useful in identifying patient cohorts
with different treatment outcomes, especially in terms of early CR in-
duction, whichwas the only independent factor inmultivariate analysis
in this study. In both training and validation groups, 78/78 (100%) and
78/78 (100%) patients of low-risk groups achieved CR, and ED tended
to occur in the high-risk group. In addition, Sanz risk stratiﬁcation was
signiﬁcant in predictingOS (Fig. 2, Table 5). However, the effect of Sanz's
Table 4
The estimated 5 year OS and DFS rates in different clinical and gene mutation groups.
Estimated 5 year OS rate
(%)
Estimated 5 year DFS rate
(%)
Sanz risk stratiﬁcation
High 80.5 ± 3.8 87.8 ± 3.4
Intermediate 89.1 ± 2.2 93.4 ± 1.9
Low 99.2 ± 0.8 96.3 ± 1.7
P, HR (95% CI) b0.001, 0.355
(0.229–0.550)
0.022, 0.554 (0.335–0.919)
FLT3
Mutated 89.9 ± 1.6 89.1 ± 4.0
Not mutated 89.4 ± 3.6 93.6 ± 1.4
P, HR (95% CI) 0.818, 1.093
(0.512–2.336)
0.188, 1.765 (0.757–4.115)
WT-1
Mutated 83.3 ± 7.6 NA*
Not mutated 89.7 ± 1.5 92.2 ± 1.4
P, HR (95% CI) 0.241, 1.845
(0.663–5.135)
0.422, 0.046
(0.000–84.431)
N-RAS
Mutated 87.0 ± 9.1 85.9 ± 9.5
Not mutated 90.2 ± 1.5 93.3 ± 1.3
P, HR (95% CI) 0.954, 0.959
(0.232–3.958)
0.617, 1.443 (0.343–6.069)
EMGs
Mutated 74.3 ± 8.0 76.7 ± 7.8
Not mutated 90.2 ± 1.6 93.9 ± 1.4
P, HR (95% CI) 0.008, 2.797
(1.305–5.998)
b0.001, 5.238
(2.225–12.332)
Double or triple
mutations
Yes 68.8 ± 11.7 78.3 ± 11.1
No 90.6 ± 1.4 93.4 ± 1.3
P, HR (95% CI) 0.008, 3.471
(1.374–8.763)
0.035, 3.6000
(1.092–11.872)
NA, not available *no relapse due to small sample size.
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Therefore, albeit the introduction of ATRA/ATO into front-line treat-
ment, risk factors adapted treatment strategy may be reconsidered.
Given the excellent results of low-risk patients (5 year OS and DFS of
99.2 ± 0.8 and 96.3 ± 1.7%, respectively), less toxic regimens such as
ATRA/ATO without chemotherapy may be used as already reported by
Lo-Coco et al., 2013. As for intermediate-risk patients, whose prognosis
was relatively poor compared to low-risk ones in our series, randomized
clinical trial is warranted to compare the results of ATRA/ATOwith che-
motherapy and those of ATRA/ATO without chemotherapy. New con-
solidation strategies containing ATO, Ara-C and other potential new
agents might be the choice for high-risk group. Of note, cases with
EMG mutations may need further enhanced therapy such as high dose
anthracyclines and regulatory agents for DNA methylation and/or his-
tone modiﬁcation to improve their clinical outcome.
In conclusion, in an era of ATRA/ATO treatment, both molecular
markers, EMG in particular, and clinical parameter based stratiﬁcationTable 5
Multivariate analysis of clinical and molecular variables for CR, OS and DFS in the pooled group
Variables CR
P OR (95% CI)
Age NS –
WBC count NS –
FLT3mutations NS –
WT1mutations 0.048 0.297 (0.089–0.988)
N-RASmutation NS –
EMG mutations NS –
Double or triple mutations NS –
Sanz risk stratiﬁcation 0.001 2.815
(1.566–5.059)systems should be used as potential prognostic factors for APL.More re-
ﬁned protocols considering the complexity ofmolecular pathogenesis of
APL such as additionalmutations should be designed, especially in high-
and intermediate-risk groups, in an attempt to cure all APL patients.
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